<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="urn:hl7-org:v3" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="11314cd7-5167-4699-e063-6394a90a93b8"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use CISPLATIN INJECTION, USP safely and effectively. See full prescribing information for CISPLATIN INJECTION, USP.
 <br/>
      <br/>
      <br/>
      <br/>
CISPLATIN injection USP, for intravenous use
 <br/>
      <br/>
      <br/>
      <br/>
Initial U.S. Approval: 1978
</title>
   <effectiveTime value="20240212"/>
   <setId root="a60c5173-6bc0-4c9d-9674-b3f4d68f79ba"/>
   <versionNumber value="4"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id root="1.3.6.1.4.1.519.1" extension="985523874"/>
            <name>BluePoint Laboratories</name>
            <assignedEntity>
               <assignedOrganization>
                  <id root="1.3.6.1.4.1.519.1" extension="604222237"/>
                  <name>Accord Healthcare</name>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="725927649"/>
                        <name>Intas Pharmaceuticals Limited</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C25391" displayName="analysis" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="68001-283" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" displayName="manufacture" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="68001-283" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84731" displayName="pack" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="68001-283" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="915837971"/>
                        <name>Intas Pharmaceuticals Limited</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C43360" displayName="manufacture" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="68001-283" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" displayName="analysis" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="68001-283" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="11317954-9a78-7e44-e063-6294a90a6ee8"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL product data elements section"/>
               <effectiveTime value="20240212"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="68001-283" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Cisplatin</name>
                        <formCode code="C42946" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Cisplatin</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="451W47IQ8X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM CHLORIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="QTT17582CB" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYDROCHLORIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="55X04QC32I" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM HYDROXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="1"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="Q20Q21Q62J" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CISPLATIN</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="Q20Q21Q62J" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>CISPLATIN</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="50" unit="mL"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="68001-283-24" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43226" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="VIAL"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="1" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="68001-283-27" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20160802"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="100" unit="mL"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="68001-283-33" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43226" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="VIAL"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="1" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="68001-283-32" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20160802"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA206774" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20160802"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38276" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INTRAVENOUS"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="ID_b5682aa8-d65f-4393-86f0-2a1fe3e0fb35">
               <id root="11314cd7-5168-4699-e063-6394a90a93b8"/>
               <code code="34066-1" codeSystem="2.16.840.1.113883.6.1" displayName="BOXED WARNING SECTION"/>
               <title>WARNING: NEPHROTOXICITY, PERIPHERAL NEUROPATHY, NAUSEA AND VOMITING and MYELOSUPPRESSION.</title>
               <text>
                  <list listType="unordered">
                     <item>
                        <content styleCode="bold">Nephrotoxicity: cisplatin injection can cause severe renal toxicity, including acute renal failure. Severe renal toxicities are dose-related and cumulative. Ensure adequate hydration and monitor renal function and electrolytes. Consider dose reductions or alternative treatments in patients with renal impairment
   
    <content styleCode="italics">[see Dosage and Administration (
    
     <linkHtml href="#ID_afab3d6b-af05-4f01-9f88-54cfeb30c56c">2.1</linkHtml>) and Warnings and Precautions (
    
     <linkHtml href="#ID_6e9a0c3a-9285-4a5a-aafd-221f0167daf1">5.1</linkHtml>)].
   
    </content>
                        </content>
                     </item>
                     <item>
                        <content styleCode="bold">Peripheral Neuropathy: cisplatin injection can cause dose-related peripheral neuropathy that becomes more severe with repeated courses of the drug
   
    <content styleCode="italics">[see Warnings and Precautions (
    
     <linkHtml href="#ID_b32f4645-dc34-4112-b218-9428a497669a">5.2</linkHtml>)].
   
    </content>
                        </content>
                     </item>
                     <item>
                        <content styleCode="bold">Nausea and Vomiting: cisplatin injection can cause severe nausea and vomiting. Use highly effective antiemetic premedication
   
    <content styleCode="italics">[see Dosage and Administration (
    
     <linkHtml href="#ID_afab3d6b-af05-4f01-9f88-54cfeb30c56c">2.1</linkHtml>) and Warnings and Precautions (
    
     <linkHtml href="#ID_ca1e8924-81c5-4f06-a8bb-e33df41b5533">5.3</linkHtml>)].
   
    </content>
                        </content>
                     </item>
                     <item>
                        <content styleCode="bold">Myelosuppression: cisplatin injection can cause severe myelosuppression with fatalities due to infections. Monitor blood counts accordingly. Interruption of therapy may be required
   
    <content styleCode="italics">[see Warnings and Precautions (
    
     <linkHtml href="#ID_c34fe9ce-c1e5-4910-8758-5dd85942e97e">5.4</linkHtml>)].
   
    </content>
                        </content>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20231231"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>WARNING: NEPHROTOXICITY, PERIPHERAL NEUROPATHY, NAUSEA AND VOMITING, and MYELOSUPPRESSION</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">See full prescribing information for complete boxed warning.</content>
                           </content>
                        </paragraph>
                        <list listType="unordered">
                           <item>
                              <content styleCode="bold">Nephrotoxicity: cisplatin injection can cause severe renal toxicity, including acute renal failure. Ensure adequate hydration. Consider dose reductions or alternative treatments in patients with renal impairment. (
   
      <linkHtml href="#ID_afab3d6b-af05-4f01-9f88-54cfeb30c56c">2.1</linkHtml>,
   
      <linkHtml href="#ID_6e9a0c3a-9285-4a5a-aafd-221f0167daf1">5.1</linkHtml>)
  
     </content>
                           </item>
                           <item>
                              <content styleCode="bold">Peripheral Neuropathy: cisplatin injection can cause dose-related peripheral neuropathy. (
   
      <linkHtml href="#ID_b32f4645-dc34-4112-b218-9428a497669a">5.2</linkHtml>)
  
     </content>
                           </item>
                           <item>
                              <content styleCode="bold">Nausea and Vomiting: cisplatin injection can cause severe nausea and vomiting. Premedicate with antiemetics. (
   
      <linkHtml href="#ID_afab3d6b-af05-4f01-9f88-54cfeb30c56c">2.1</linkHtml>,
   
      <linkHtml href="#ID_ca1e8924-81c5-4f06-a8bb-e33df41b5533">5.3</linkHtml>)
  
     </content>
                           </item>
                           <item>
                              <content styleCode="bold">Myelosuppression: cisplatin injection can cause severe myelosuppression with fatalities due to infections. Monitor blood counts and interrupt therapy accordingly. (
   
      <linkHtml href="#ID_c34fe9ce-c1e5-4910-8758-5dd85942e97e">5.4</linkHtml>)
  
     </content>
                           </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID_ab12ba73-d31a-49a0-ac10-247ba984a94b">
               <id root="11314cd7-5169-4699-e063-6394a90a93b8"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE</title>
               <effectiveTime value="20231231"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Cisplatin injection is a platinum-based drug indicated for the treatment of:</paragraph>
                        <paragraph>• Advanced testicular cancer (
 
    <linkHtml href="#ID_022f1d85-553d-486f-a338-0b17f0ebc7b3">1.1</linkHtml>)

   </paragraph>
                        <paragraph>• Advanced ovarian cancer (
 
    <linkHtml href="#ID_9a8eb980-4c91-4e17-9fa3-268e191d6351">1.2</linkHtml>)

   </paragraph>
                        <paragraph>• Advanced bladder cancer (
 
    <linkHtml href="#ID_7b00282f-49c8-4077-9986-35405decefd5">1.3</linkHtml>)

   </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID_022f1d85-553d-486f-a338-0b17f0ebc7b3">
                     <id root="11314cd7-516a-4699-e063-6394a90a93b8"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>1.1 Advanced Testicular Cancer</title>
                     <text>
                        <paragraph>Cisplatin injection is indicated for the treatment of advanced testicular cancer.</paragraph>
                     </text>
                     <effectiveTime value="20231231"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_9a8eb980-4c91-4e17-9fa3-268e191d6351">
                     <id root="11314cd7-516b-4699-e063-6394a90a93b8"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>1.2 Advanced Ovarian Cancer</title>
                     <text>
                        <paragraph>Cisplatin injection is indicated for the treatment of advanced ovarian cancer.</paragraph>
                     </text>
                     <effectiveTime value="20231231"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_7b00282f-49c8-4077-9986-35405decefd5">
                     <id root="11314cd7-516c-4699-e063-6394a90a93b8"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>1.3 Advanced Bladder Cancer</title>
                     <text>
                        <paragraph>Cisplatin injection is indicated for the treatment of advanced bladder cancer.</paragraph>
                     </text>
                     <effectiveTime value="20231231"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_1b8733c2-d459-4891-9a53-a0c935dbeabc">
               <id root="11314cd7-516d-4699-e063-6394a90a93b8"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION</title>
               <effectiveTime value="20231231"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>• Administer pre-treatment hydration and pre- and post-treatment antiemetics. (
 
    <linkHtml href="#ID_afab3d6b-af05-4f01-9f88-54cfeb30c56c">2.1</linkHtml>)

   </paragraph>
                        <paragraph>• Cisplatin injection has been administered intravenously at:</paragraph>
                        <list listType="ordered">
                           <item>Advanced testicular cancer: 20 mg/m2 daily for 5 days per cycle (
  
     <linkHtml href="#ID_585542ba-04ab-4224-96a6-1922fed4e5f4">2.2</linkHtml>)
 
    </item>
                           <item>Advanced ovarian cancer: 75 mg/m2 to 100 mg/m2 per cycle once every 3 to 4 weeks (
  
     <linkHtml href="#ID_aaac87ac-6cf3-4b1f-93fa-b24f220d2d86">2.3</linkHtml>)
 
    </item>
                           <item>Advanced bladder cancer: 50 mg/m2 to 70 mg/m2 intravenously per cycle once every 3 to 4 weeks (
  
     <linkHtml href="#ID_51318cd0-94c7-484b-9c25-2cc2fa69095e">2.4</linkHtml>)
 
    </item>
                           <item>Refer to current treatment guidelines for specific dosing information.</item>
                        </list>
                        <paragraph>• Administer by slow intravenous infusion. Avoid contact of cisplatin injection with aluminum parts. (
 
    <linkHtml href="#ID_a1f03959-105a-448f-b3f0-26eefd396af1">2.6</linkHtml>)

   </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID_afab3d6b-af05-4f01-9f88-54cfeb30c56c">
                     <id root="11314cd7-516e-4699-e063-6394a90a93b8"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.1 Hydration and Anti-Emetic Treatment</title>
                     <text>
                        <paragraph>Patients treated with cisplatin injection must receive appropriate pre-treatment hydration. Maintain adequate hydration and urinary output for 24 hours after cisplatin injection administration
 
  <content styleCode="italics">[see Warnings and Precautions (
  
   <linkHtml href="#ID_6e9a0c3a-9285-4a5a-aafd-221f0167daf1">5.1</linkHtml>)]
 
  </content>. Administer pre-treatment and post-treatment antiemetics as appropriate
 
  <content styleCode="italics">[see Warnings and Precautions (
  
   <linkHtml href="#ID_753390e9-27e5-450a-9cb8-96e0b4ecfea4">5.7</linkHtml>)]
 
  </content>.

 </paragraph>
                     </text>
                     <effectiveTime value="20231231"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_585542ba-04ab-4224-96a6-1922fed4e5f4">
                     <id root="11314cd7-516f-4699-e063-6394a90a93b8"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.2 Advanced Testicular Cancer</title>
                     <text>
                        <paragraph>Cisplatin injection has been administered at 20 mg/m
 
  <sup>2</sup>intravenously daily for 5 days per cycle. Other doses and combination regimens have been used.

 </paragraph>
                     </text>
                     <effectiveTime value="20231231"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_aaac87ac-6cf3-4b1f-93fa-b24f220d2d86">
                     <id root="11314cd7-5170-4699-e063-6394a90a93b8"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.3 Advanced Ovarian Cancer</title>
                     <text>
                        <paragraph>Cisplatin injection has been administered at 75 mg/m
 
  <sup>2</sup>to 100 mg/m
 
  <sup>2</sup>intravenously per cycle once every 3 to 4 weeks on Day 1. Other doses and combination regimens have been used.

 </paragraph>
                     </text>
                     <effectiveTime value="20231231"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_51318cd0-94c7-484b-9c25-2cc2fa69095e">
                     <id root="11314cd7-5171-4699-e063-6394a90a93b8"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.4 Advanced Bladder Cancer</title>
                     <text>
                        <paragraph>Cisplatin injection has been administered at 50 mg/m
 
  <sup>2</sup>to 70 mg/m
 
  <sup>2</sup>intravenously per cycle once every 3 to 4 weeks. For heavily pretreated patients, an initial dose of 50 mg/m
 
  <sup>2</sup>per cycle repeated every 4 weeks is recommended. Other doses and combination in regimens have been used.

 </paragraph>
                     </text>
                     <effectiveTime value="20231231"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_f54f361a-b76e-4f4d-9e0a-7d8077a9af08">
                     <id root="11314cd7-5172-4699-e063-6394a90a93b8"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.5 Dose Modifications</title>
                     <text>
                        <paragraph>Consider alternative treatments or dose reductions for patients with impaired creatinine clearance, myelosuppression, or neuropathy. Consider permanent discontinuation for Grade 3-4 neuropathy.
 
  <content styleCode="italics">[See Warnings and Precautions (
  
   <linkHtml href="#ID_6e9a0c3a-9285-4a5a-aafd-221f0167daf1">5.1</linkHtml>)]
 
  </content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20231231"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_a1f03959-105a-448f-b3f0-26eefd396af1">
                     <id root="11314cd7-5173-4699-e063-6394a90a93b8"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.6 Preparation, Handling, and Administration</title>
                     <text>
                        <paragraph>Do not use needles or intravenous sets containing aluminum parts that can come in contact with cisplatin injection during preparation or administration. Aluminum reacts with cisplatin injection, causing precipitate formation and a loss of potency.</paragraph>
                        <paragraph>Cisplatin injection is a cytotoxic drug. Follow applicable special handling and disposable procedures.
 
  <sup>1</sup>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">Instructions for Preparation</content>
                        </paragraph>
                        <paragraph>The aqueous solution should be used intravenously only and should be administered by IV infusion over a 6- to 8-hour period (see
 
  <content styleCode="bold">
                              <linkHtml href="#ID_1b8733c2-d459-4891-9a53-a0c935dbeabc">DOSAGE AND ADMINISTRATION</linkHtml>
                           </content>).

 </paragraph>
                        <paragraph>Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.</paragraph>
                        <paragraph>
                           <content styleCode="bold">NOTE TO PHARMACIST:</content>Exercise caution to prevent inadvertent cisplatin overdosage. Please call prescriber if dose is greater than 100 mg/m
 
  <sup>2</sup>per cycle. Aluminum flip-off seal of vial have been imprinted with the following statement: 
  <br/>
                           <content styleCode="bold">CALL DR. IF DOSE &gt; 100 MG/M
  
   <sup>2</sup>/CYCLE.
 
  </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Administration</content>
                           </content>
                        </paragraph>
                        <paragraph>Administer cisplatin injection by slow intravenous infusion.</paragraph>
                     </text>
                     <effectiveTime value="20231231"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_6ed8fcef-8de7-462c-b886-a4e1919f4cc9">
               <id root="11314cd7-5174-4699-e063-6394a90a93b8"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <paragraph>Cisplatin injection USP, is a clear, colorless to pale yellow, sterile aqueous solution available in sterile multiple-dose vials containing</paragraph>
                  <list listType="unordered">
                     <item>50 mg/50 mL (1 mg/mL)</item>
                     <item>100 mg/100 mL (1 mg/mL)</item>
                  </list>
               </text>
               <effectiveTime value="20231231"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Cisplatin injection USP, is multiple-dose vials containing</paragraph>
                        <list listType="unordered">
                           <item>50 mg/50 mL (1 mg/mL) (
  
     <linkHtml href="#ID_6ed8fcef-8de7-462c-b886-a4e1919f4cc9">3</linkHtml>)
 
    </item>
                           <item>100 mg/100 mL (1 mg/mL) (
  
     <linkHtml href="#ID_6ed8fcef-8de7-462c-b886-a4e1919f4cc9">3</linkHtml>)
 
    </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID_6eb7f564-05d7-4ee8-bfd4-16ead4935c4d">
               <id root="11314cd7-5175-4699-e063-6394a90a93b8"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS</title>
               <text>
                  <paragraph>Cisplatin injection is contraindicated in patients with severe hypersensitivity to cisplatin
 
  <content styleCode="italics">[see Warnings and Precautions (
  
   <linkHtml href="#ID_c34fe9ce-c1e5-4910-8758-5dd85942e97e">5.4</linkHtml>)]
 
  </content>.

 </paragraph>
               </text>
               <effectiveTime value="20231231"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Severe hypersensitivity to cisplatin (
 
    <linkHtml href="#ID_6eb7f564-05d7-4ee8-bfd4-16ead4935c4d">4</linkHtml>)

   </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID_db378455-2571-48bf-aaa0-1ad6629604bc">
               <id root="11314cd7-5176-4699-e063-6394a90a93b8"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS</title>
               <effectiveTime value="20231231"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>Hypersensitivity reactions: Anaphylaxis and death may occur; monitor for and treat accordingly (
  
     <linkHtml href="#ID_340f4fb1-e3e9-48c5-96cd-368f5e6a0efd">5.5</linkHtml>)
 
    </item>
                           <item>Ototoxicity: Cumulative toxicity may be severe particularly in pediatric patients; consider audiometric and vestibular function monitoring (
  
     <linkHtml href="#ID_e9fa4e2b-c9f5-45e8-9322-baf1fa26c5e7">5.6</linkHtml>,
  
     <linkHtml href="#ID_d8061103-124a-40ea-9ed8-fc0812128d22">8.4</linkHtml>)
 
    </item>
                           <item>Ocular toxicity: Optic neuritis, papilledema, and cortical blindness may occur (
  
     <linkHtml href="#ID_753390e9-27e5-450a-9cb8-96e0b4ecfea4">5.7</linkHtml>)
 
    </item>
                           <item>Secondary leukemia: Secondary acute leukemia may occur (
  
     <linkHtml href="#ID_10398218-037c-49d7-a8f9-ad7941942423">5.8</linkHtml>)
 
    </item>
                           <item>Embryo-fetal toxicity: Can cause fetal harm. Advise of potential risk to a fetus and use of effective contraception. (
  
     <linkHtml href="#ID_99ae58c0-ddba-40b6-a23a-2368409dc02b">5.9</linkHtml>,
  
     <linkHtml href="#ID_0cdb87bd-bbc7-45a2-af4c-d769680df6de">8.1</linkHtml>,
  
     <linkHtml href="#ID_00712a6a-6a34-4f21-9f37-f7bec57bf4f6">8.3</linkHtml>)
 
    </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID_6e9a0c3a-9285-4a5a-aafd-221f0167daf1">
                     <id root="11314cd7-5177-4699-e063-6394a90a93b8"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1 Nephrotoxicity</title>
                     <text>
                        <paragraph>Cisplatin injection can cause dose-related nephrotoxicity, including acute renal failure that becomes more prolonged and severe with repeated courses of the drug. Renal toxicity typically begins during the second week after a dose of cisplatin injection. Patients with baseline renal impairment, geriatric patients, patients who are taking other nephrotoxic drugs, or patients who are not well hydrated may be more susceptible to nephrotoxicity
 
  <content styleCode="italics">[see Use in Specific Populations (
  
   <linkHtml href="#ID_4f8f43e8-3652-4cfe-a07e-73e9be930c61">8.5</linkHtml>,
  
   <linkHtml href="#ID_3c6cb848-62fe-460f-be4a-44e94490ba7d">8.6</linkHtml>)]
 
  </content>.

 </paragraph>
                        <paragraph>Ensure adequate hydration before, during, and after cisplatin injection administration
 
  <content styleCode="italics">[see Dosage and Administration (
  
   <linkHtml href="#ID_afab3d6b-af05-4f01-9f88-54cfeb30c56c">2.1</linkHtml>)]
 
  </content>. Measure serum creatinine, blood urea nitrogen, creatinine clearance, and serum electrolytes including magnesium prior to initiating therapy, and as clinically indicated. Consider magnesium supplementation as clinically needed.

 </paragraph>
                        <paragraph>Consider alternative treatments or reduce the dose of cisplatin injection for patients with baseline renal impairment or who develop significant reductions in creatinine clearance during treatment with cisplatin injection according to clinical treatment guidelines
 
  <content styleCode="italics">[see Dosage and Administration(
  
   <linkHtml href="#ID_f54f361a-b76e-4f4d-9e0a-7d8077a9af08">2.5</linkHtml>)].
 
  </content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20231231"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_b32f4645-dc34-4112-b218-9428a497669a">
                     <id root="11314cd7-5178-4699-e063-6394a90a93b8"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.2 Peripheral Neuropathy</title>
                     <text>
                        <paragraph>Cisplatin injection can cause dose-related peripheral neuropathy that becomes more severe with repeated courses of the drug. Neurologic symptoms have been reported to occur after a single dose. Neuropathy can also have a delayed onset from 3 to 8 weeks after the last dose of cisplatin injection. Manifestations include paresthesias in a stocking-glove distribution, areflexia, and loss of proprioception and vibratory sensation. The neuropathy may progress further even after stopping treatment. Peripheral neuropathy may be irreversible in some patients.</paragraph>
                        <paragraph>Perform a neurological examination before initiating cisplatin injection, at appropriate intervals during therapy, and after completion of therapy. Consider discontinuation of cisplatin injection for patients who develop symptomatic peripheral neuropathy. Geriatric patients may be more susceptible to peripheral neuropathy
 
  <content styleCode="italics">[see Use in Specific Populations (
  
   <linkHtml href="#ID_4f8f43e8-3652-4cfe-a07e-73e9be930c61">8.5</linkHtml>)]
 
  </content>.

 </paragraph>
                     </text>
                     <effectiveTime value="20231231"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_ca1e8924-81c5-4f06-a8bb-e33df41b5533">
                     <id root="11314cd7-5179-4699-e063-6394a90a93b8"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.3 Nausea and Vomiting</title>
                     <text>
                        <paragraph>Cisplatin injection is a highly emetogenic antineoplastic agent. Premedicate with anti-emetic agents
 
  <content styleCode="italics">[see Dosage and Administration (
  
   <linkHtml href="#ID_afab3d6b-af05-4f01-9f88-54cfeb30c56c">2.1</linkHtml>)]
 
  </content>. Without antiemetic therapy, marked nausea and vomiting occur in almost all patients treated with cisplatin injection and may be so severe that the drug must be discontinued. Nausea and vomiting may begin within 1 to 4 hours after treatment and last up to 72 hours. Maximal intensity occurs 48 to 72 hours after administration. Various degrees of vomiting, nausea, and/or anorexia may persist for up to 1 week after treatment. Delayed nausea and vomiting (begins or persists 24 hours or more after chemotherapy) has occurred in patients attaining complete emetic control on the day of cisplatin injection therapy. Consider the use of additional anti-emetics following infusion.

 </paragraph>
                     </text>
                     <effectiveTime value="20231231"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_c34fe9ce-c1e5-4910-8758-5dd85942e97e">
                     <id root="11314cd7-517a-4699-e063-6394a90a93b8"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.4 Myelosuppression</title>
                     <text>
                        <paragraph>Myelosuppression suppression occurs in 25% to 30% of patients treated with cisplatin injection. Fever and infection have been reported in patients with neutropenia. Potential fatalities due to infection (secondary to myelosuppression) have been reported. Geriatric patients may be more susceptible to myelosuppression
 
  <content styleCode="italics">[see Use in Specific Populations (
  
   <linkHtml href="#ID_4f8f43e8-3652-4cfe-a07e-73e9be930c61">8.5</linkHtml>)]
 
  </content>.

 </paragraph>
                        <paragraph>Perform standard hematologic tests before initiating cisplatin injection, before each subsequent course, and as clinically indicated. Closely monitor patients for the development of signs and symptoms of infection during and after treatment with cisplatin injection. For patients who develop severe myelosuppression during treatment with cisplatin injection, consider dose modifications and manage according to clinical treatment guidelines.</paragraph>
                     </text>
                     <effectiveTime value="20231231"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_340f4fb1-e3e9-48c5-96cd-368f5e6a0efd">
                     <id root="11314cd7-517b-4699-e063-6394a90a93b8"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.5 Hypersensitivity Reactions</title>
                     <text>
                        <paragraph>Cisplatin injection can cause severe hypersensitivity reactions, including anaphylaxis and death. Manifestations have included facial edema, wheezing, tachycardia, and hypotension. Hypersensitivity reactions have occurred within minutes of administration to patients with prior exposure tocisplatin injection.</paragraph>
                        <paragraph>Monitor patients receiving cisplatin injection for possible hypersensitivity reactions. Ensure supportive equipment and medications are available to treat severe hypersensitivity reactions. Severe hypersensitivity reactions require immediate discontinuation of cisplatin injection and aggressive therapy. Patients with a history of severe hypersensitivity reactions should not be rechallenged with cisplatin injection
 
  <content styleCode="italics">[see Contraindications (
  
   <linkHtml href="#ID_6eb7f564-05d7-4ee8-bfd4-16ead4935c4d">4</linkHtml>)]
 
  </content>. Cross-reactivity between platinum-based antineoplastic agents has been reported. Cases of severe hypersensitivity reactions have recurred after rechallenging patients with a different platinum agent.

 </paragraph>
                     </text>
                     <effectiveTime value="20231231"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_e9fa4e2b-c9f5-45e8-9322-baf1fa26c5e7">
                     <id root="11314cd7-517c-4699-e063-6394a90a93b8"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.6 Ototoxicity</title>
                     <text>
                        <paragraph>Cisplatin injection can cause ototoxicity, which is cumulative and may be severe. Consider audiometric and vestibular function monitoring.</paragraph>
                        <paragraph>Ototoxicity is manifested by tinnitus, hearing loss in the high frequency range (4,000 to 8,000 Hz) and/or decreased ability to hear normal conversational tones. Ototoxicity can occur during or after treatment and can be unilateral or bilateral. Deafness after the initial dose of cisplatin injection has been reported. Vestibular toxicity has also been reported.</paragraph>
                        <paragraph>Ototoxic effects can be more severe and detrimental in pediatric patients, particularly in patients less than 5 years of age. The prevalence of hearing loss in pediatric patients is estimated to be 40-60%. Additional risk factors for ototoxicity include simultaneous cranial irradiation, treatment with other ototoxic drugs and renal impairment. Consider audiometric and vestibular testing in all pediatric patients receiving cisplatin
 
  <content styleCode="italics">[see Use in Specific Populations (
  
   <linkHtml href="#ID_d8061103-124a-40ea-9ed8-fc0812128d22">8.4</linkHtml>)].
 
  </content>
                        </paragraph>
                        <paragraph>Genetic factors (e.g. variants in the thiopurine S-methyltransferase [TPMT] gene) may also contribute to the cisplatin-induced ototoxicity; although this association has not been consistent across populations and study designs.</paragraph>
                     </text>
                     <effectiveTime value="20231231"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_753390e9-27e5-450a-9cb8-96e0b4ecfea4">
                     <id root="11314cd7-517d-4699-e063-6394a90a93b8"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.7 Ocular Toxicity</title>
                     <text>
                        <paragraph>Optic neuritis, papilledema, and cortical blindness have been reported in patients receiving standard recommended doses of cisplatin injection. Blurred vision and altered color perception have been reported after the use of regimens with higher doses and dose frequencies of cisplatin injection. The altered color perception manifests as a loss of color discrimination, particularly in the blue-yellow axis and irregular retinal pigmentation of the macular area on fundoscopic exam. Improvement and/or total recovery usually occurs after discontinuing cisplatin injection but can be delayed.</paragraph>
                     </text>
                     <effectiveTime value="20231231"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_10398218-037c-49d7-a8f9-ad7941942423">
                     <id root="11314cd7-517e-4699-e063-6394a90a93b8"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.8 Secondary Malignancies</title>
                     <text>
                        <paragraph>The development of acute leukemia secondary to the use of cisplatin injection has been reported. In these reports, cisplatin injection was generally given in combination with other leukemogenic agents.</paragraph>
                     </text>
                     <effectiveTime value="20231231"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_99ae58c0-ddba-40b6-a23a-2368409dc02b">
                     <id root="11314cd7-517f-4699-e063-6394a90a93b8"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.9 Embryo-Fetal Toxicity</title>
                     <text>
                        <paragraph>Based on human data, cisplatin injection can cause fetal harm when administered to a pregnant woman. Advise pregnant women and females of reproductive potential of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment and for 14 months after the last dose of cisplatin injection. Advise male patients with female partners of reproductive potential to use effective contraception during treatment and for 11 months after the last dose of cisplatin injection
 
  <content styleCode="italics">[see Use in Specific Populations (
  
   <linkHtml href="#ID_0cdb87bd-bbc7-45a2-af4c-d769680df6de">8.1</linkHtml>,
  
   <linkHtml href="#ID_00712a6a-6a34-4f21-9f37-f7bec57bf4f6">8.3</linkHtml>)].
 
  </content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20231231"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_ff697fa0-9ac6-48c7-891f-cc476f99155d">
                     <id root="11314cd7-5180-4699-e063-6394a90a93b8"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.10 Injection Site Reactions</title>
                     <text>
                        <paragraph>Injection site reactions can occur during the administration of cisplatin injection. Local soft tissue toxicity has been reported following extravasation of cisplatin injection. Severity of the local tissue toxicity appears to be related to the concentration of the cisplatin injection solution. Infusion of solutions with a cisplatin injection concentration greater than 0.5 mg/mL may result in tissue cellulitis, fibrosis, necrosis, pain, edema, and erythema.</paragraph>
                        <paragraph>Because of the possibility of extravasation, closely monitor the infusion site during drug administration.</paragraph>
                     </text>
                     <effectiveTime value="20231231"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_e0085771-db72-48f6-860e-b94b7b8d6336">
               <id root="11314cd7-5181-4699-e063-6394a90a93b8"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS</title>
               <text>
                  <paragraph>The following adverse reactions are described in greater detail, in other sections:</paragraph>
                  <list listType="unordered">
                     <item>Nephrotoxicity
  
   <content styleCode="italics">[see Warnings and Precautions (
   
    <linkHtml href="#ID_6e9a0c3a-9285-4a5a-aafd-221f0167daf1">5.1</linkHtml>)]
  
   </content>
                     </item>
                     <item>Peripheral Neuropathy
  
   <content styleCode="italics">[see Warnings and Precautions (
   
    <linkHtml href="#ID_b32f4645-dc34-4112-b218-9428a497669a">5.2</linkHtml>)]
  
   </content>
                     </item>
                     <item>Nausea and vomiting
  
   <content styleCode="italics">[see Warnings and Precautions (
   
    <linkHtml href="#ID_ca1e8924-81c5-4f06-a8bb-e33df41b5533">5.3</linkHtml>)]
  
   </content>
                     </item>
                     <item>Myelosuppression
  
   <content styleCode="italics">[see Warnings and Precautions (
   
    <linkHtml href="#ID_c34fe9ce-c1e5-4910-8758-5dd85942e97e">5.4</linkHtml>)]
  
   </content>
                     </item>
                     <item>Hypersensitivity reactions
  
   <content styleCode="italics">[see Warnings and Precautions (
   
    <linkHtml href="#ID_c34fe9ce-c1e5-4910-8758-5dd85942e97e">5.5</linkHtml>)]
  
   </content>
                     </item>
                     <item>Ototoxicity
  
   <content styleCode="italics">[see Warnings and Precautions (
   
    <linkHtml href="#ID_e9fa4e2b-c9f5-45e8-9322-baf1fa26c5e7">5.6</linkHtml>]
  
   </content>
                     </item>
                     <item>Ocular toxicity
  
   <content styleCode="italics">[see Warnings and Precautions (
   
    <linkHtml href="#ID_753390e9-27e5-450a-9cb8-96e0b4ecfea4">5.7</linkHtml>)]
  
   </content>
                     </item>
                     <item>Secondary malignancies
  
   <content styleCode="italics">[see Warnings and Precautions (
   
    <linkHtml href="#ID_10398218-037c-49d7-a8f9-ad7941942423">5.8</linkHtml>)]
  
   </content>
                     </item>
                     <item>Injection site reactions
  
   <content styleCode="italics">[see Warnings and Precautions (
   
    <linkHtml href="#ID_ff697fa0-9ac6-48c7-891f-cc476f99155d">5.10</linkHtml>)]
  
   </content>
                     </item>
                  </list>
                  <paragraph>Common adverse reactions are nephrotoxicity, peripheral neuropathy, nausea and vomiting myelosuppression, and ototoxicity. The following adverse reactions have been identified from clinical trials or post-marketing surveillance.</paragraph>
                  <paragraph>
                     <content styleCode="italics">Blood and lymphatic system disorders:</content>Coombs‑positive hemolytic anemia. hemolytic uremic syndrome, thrombotic thrombocytopenic purpura

 </paragraph>
                  <paragraph>
                     <content styleCode="italics">Cardiovascular disorders:</content>Venous thromboembolism, arterial thromboembolism, myocardial infarction, cerebrovascular accident, thrombotic microangiopathy, cerebral arteritis, pericardial effusion, cardiac failure, ventricular dysfunction, Raynaud’s phenomenon

 </paragraph>
                  <paragraph>
                     <content styleCode="italics">Eye disorders:</content>Optic neuritis, papilledema, cortical blindness, blurred vision, color blindness, retinal pigmentation

 </paragraph>
                  <paragraph>
                     <content styleCode="italics">Gastrointestinal disorders:</content>Nausea, vomiting, anorexia, diarrhea, stomatitis, gastrointestinal perforation, pancreatitis, hiccups

 </paragraph>
                  <paragraph>
                     <content styleCode="italics">General disorders:</content>Asthenia, malaise

 </paragraph>
                  <paragraph>
                     <content styleCode="italics">Hepatobiliary disorders:</content>Elevations of aminotransferases, lactate dehydrogenase, and bilirubin; hepatic failure

 </paragraph>
                  <paragraph>
                     <content styleCode="italics">Hypersensitivity:</content>Anaphylaxis, facial edema, wheezing, tachycardia, and hypotension

 </paragraph>
                  <paragraph>
                     <content styleCode="italics">Local Site Reactions:</content>Tissue cellulitis, fibrosis, necrosis, pain, edema, and erythema

 </paragraph>
                  <paragraph>
                     <content styleCode="italics">Metabolism and nutrition disorders:</content>Hypomagnesemia, often requiring magnesium supplementation; hyperuricemia, other electrolyte abnormalities (hypocalcemia, hyponatremia, hypokalemia, and hypophosphatemia), Syndrome of Inappropriate Antidiuretic Hormone Excretion (SIADH), dehydration, tumor lysis syndrome, increased serum amylase

 </paragraph>
                  <paragraph>
                     <content styleCode="italics">Musculoskeletal disorders:</content>Muscle cramps (localized, painful, involuntary skeletal muscle contractions of sudden onset and short duration)

 </paragraph>
                  <paragraph>
                     <content styleCode="italics">Nervous system disorders:</content>Peripheral neuropathy, Encephalopathy, loss of motor function, loss of taste, leukoencephalopathy, reversible posterior leukoencephalopathy syndrome, progressive multifocal leukoencephalopathy, seizures, Lhermitte’s sign, dorsal column myelopathy, autonomic neuropathy, seizures, involuntary skeletal muscle contractions, tetany (with hypocalcemia and hypomagnesemia)

 </paragraph>
                  <paragraph>
                     <content styleCode="italics">Ototoxicity:</content>Tinnitus, hearing loss, deafness, vestibular toxicity

 </paragraph>
                  <paragraph>
                     <content styleCode="italics">Renal and urinary disorders:</content>Nephrotoxicity including renal failure, renal electrolyte wasting, azotemia, decreased creatinine clearance

 </paragraph>
                  <paragraph>
                     <content styleCode="italics">Respiratory disorders:</content>pneumonitis/interstitial lung disease, pulmonary embolism

 </paragraph>
                  <paragraph>
                     <content styleCode="italics">Skin and subcutaneous tissue disorders:</content>Alopecia, rash

 </paragraph>
               </text>
               <effectiveTime value="20231231"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Common adverse reactions are nephrotoxicity, peripheral neuropathy, nausea and vomiting, myelosuppression, and ototoxicity. (
 
    <linkHtml href="#ID_e0085771-db72-48f6-860e-b94b7b8d6336">6</linkHtml>)

   </paragraph>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Accord Healthcare Inc. at 1-866-941-7875 or FDA at 1-800-FDA-1088 or
  
     <content styleCode="italics">
                                 <linkHtml href="http://www.fda.gov/medwatch">www.fda.gov/medwatch</linkHtml>
                              </content>.
 
    </content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID_12840b3f-00d5-4e3e-8fd3-40cd860ac65e">
               <id root="11314cd7-5182-4699-e063-6394a90a93b8"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7 DRUG INTERACTIONS</title>
               <text>
                  <paragraph>The following drug interactions are described in other sections:</paragraph>
                  <list listType="unordered">
                     <item>Nephrotoxic drugs
  
   <content styleCode="italics">[see Warnings and Precautions (
   
    <linkHtml href="#ID_6e9a0c3a-9285-4a5a-aafd-221f0167daf1">5.1</linkHtml>)]
  
   </content>
                     </item>
                     <item>Ototoxic drugs
  
   <content styleCode="italics">[see Warnings and Precautions (
   
    <linkHtml href="#ID_e9fa4e2b-c9f5-45e8-9322-baf1fa26c5e7">5.6</linkHtml>)]
  
   </content>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20231231"/>
            </section>
         </component>
         <component>
            <section ID="ID_c16c3856-bf49-48f7-bf69-deb3d792cf8b">
               <id root="11314cd7-5183-4699-e063-6394a90a93b8"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS</title>
               <effectiveTime value="20231231"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>Lactation: Advise not to breastfeed. (
  
     <linkHtml href="#ID_2ba9d705-6681-4a33-bc2a-cd085d18d5ed">8.2</linkHtml>)
 
    </item>
                           <item>Females and Males of Reproductive Potential: Verify pregnancy status prior to initiation of cisplatin injection. Can impair fertility. (
  
     <linkHtml href="#ID_00712a6a-6a34-4f21-9f37-f7bec57bf4f6">8.3</linkHtml>)
 
    </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID_0cdb87bd-bbc7-45a2-af4c-d769680df6de">
                     <id root="11314cd7-5184-4699-e063-6394a90a93b8"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary</content>
                        </paragraph>
                        <paragraph>Based on human data from published literature, cisplatin injection can cause fetal harm when administered to pregnant women. Advise pregnant women and females of reproductive potential of the potential risk to a fetus. Data demonstrates transplacental transfer of cisplatin. Exposure of pregnant women to cisplatin-containing chemotherapy has been associated with oligohydramnios, intrauterine growth restriction, and preterm birth. Cases of neonatal acute respiratory distress syndrome, cytopenias, and hearing loss have been reported. Cisplatin injection administration to animals during and after organogenesis resulted in teratogenicity. A published study in mice showed placental transfer of cisplatin increased with placenta maturation.</paragraph>
                        <paragraph>The background risk of major birth defects and miscarriage for the indicated populations are unknown. However, the background risk in the U.S. general population of major birth defects is 2-4% and of miscarriage is 15-20% of clinically recognized pregnancies.</paragraph>
                     </text>
                     <effectiveTime value="20231231"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_2ba9d705-6681-4a33-bc2a-cd085d18d5ed">
                     <id root="11314cd7-5185-4699-e063-6394a90a93b8"/>
                     <code code="77290-5" codeSystem="2.16.840.1.113883.6.1" displayName="LACTATION SECTION"/>
                     <title>8.2 Lactation</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary</content>
                        </paragraph>
                        <paragraph>Limited data from published literature report the presence of cisplatin in human milk in low amounts. Because of the potential for serious adverse reactions from cisplatin injection in a breastfed child and because of the potential for tumorigenicity shown for cisplatin injection, advise lactating women not to breastfeed during treatment with cisplatin injection.</paragraph>
                     </text>
                     <effectiveTime value="20231231"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_00712a6a-6a34-4f21-9f37-f7bec57bf4f6">
                     <id root="11314cd7-5186-4699-e063-6394a90a93b8"/>
                     <code code="77291-3" codeSystem="2.16.840.1.113883.6.1" displayName="FEMALES &amp; MALES OF REPRODUCTIVE POTENTIAL SECTION"/>
                     <title>8.3 Females and Males of Reproductive Potential</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Pregnancy Testing</content>
                        </paragraph>
                        <paragraph>Verify the pregnancy status of females of reproductive potential prior to initiation of cisplatin injection.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Contraception</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Females</content>
                        </paragraph>
                        <paragraph>Cisplatin injection can cause fetal harm when administered to a pregnant woman
 
  <content styleCode="italics">[see Use in Specific Populations (
  
   <linkHtml href="#ID_0cdb87bd-bbc7-45a2-af4c-d769680df6de">8.1</linkHtml>)]
 
  </content>. Advise females of reproductive potential to use effective contraception during treatment and for 14 months following the last dose of cisplatin injection.

 </paragraph>
                        <paragraph>
                           <content styleCode="italics">Males</content>
                        </paragraph>
                        <paragraph>Advise male patients with female partners of reproductive potential to use effective contraception during treatment and for 11 months after the last dose of cisplatin injection.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Infertility</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Females</content>
                        </paragraph>
                        <paragraph>The use of cisplatin has been associated with cumulative dose-dependent ovarian failure, premature menopause, and reduced fertility.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Males</content>
                        </paragraph>
                        <paragraph>The use of cisplatin has been associated with a cumulative dose-dependent impairment of spermatogenesis (oligospermia, azoospermia; possibly irreversible) and reduced fertility.</paragraph>
                     </text>
                     <effectiveTime value="20231231"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_d8061103-124a-40ea-9ed8-fc0812128d22">
                     <id root="11314cd7-5187-4699-e063-6394a90a93b8"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use</title>
                     <text>
                        <paragraph>Ototoxic effects may be more severe and detrimental in pediatric patients receiving cisplatin injection, particularly in patients less than 5 years of age. Consider audiometric and vestibular function monitoring in all patients receiving cisplatin injection. The prevalence of hearing loss in pediatric patients is particularly high and is estimated to be 40% to 60%.</paragraph>
                        <paragraph>Earlier detection of hearing loss can limit the potential impact of hearing impairment on a pediatric patient’s cognitive and social development
 
  <content styleCode="italics">[see Warnings and Precautions (
  
   <linkHtml href="#ID_e9fa4e2b-c9f5-45e8-9322-baf1fa26c5e7">5.6</linkHtml>)].
 
  </content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20231231"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_4f8f43e8-3652-4cfe-a07e-73e9be930c61">
                     <id root="11314cd7-5188-4699-e063-6394a90a93b8"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use</title>
                     <text>
                        <paragraph>For the treatment of metastatic testicular tumors or advanced bladder cancer, clinical studies of cisplatin injection did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. In four clinical trials of combination chemotherapy for advanced ovarian carcinoma, 1,484 patients received cisplatin either in combination with cyclophosphamide or with paclitaxel. Of these, 426 (29%) were older than 65 years. In these trials, age was not found to be a prognostic factor for survival. However, in a later secondary analysis for one of these trials, geriatric patients were found to have shorter survival compared with younger patients.</paragraph>
                        <paragraph>In all four trials, geriatric patients experienced more severe neutropenia than did younger patients. Higher incidences of severe thrombocytopenia and leukopenia were also seen in geriatric patients compared with younger patients, although not in all cisplatin-containing treatment arms. In the two trials where nonhematologic toxicity was evaluated according to age, geriatric patients had a numerically higher incidence of peripheral neuropathy than did younger patients. Other reported clinical experience suggests that geriatric patients may be more susceptible to nephrotoxicity, myelosuppression, and infectious complications than are younger patients
 
  <content styleCode="italics">[see Warnings and Precautions (
  
   <linkHtml href="#ID_6e9a0c3a-9285-4a5a-aafd-221f0167daf1">5.1</linkHtml>,
  
   <linkHtml href="#ID_b32f4645-dc34-4112-b218-9428a497669a">5.2</linkHtml>,
  
   <linkHtml href="#ID_c34fe9ce-c1e5-4910-8758-5dd85942e97e">5.4</linkHtml>)].
 
  </content>
                        </paragraph>
                        <paragraph>Cisplatin is known to be substantially excreted by the kidney. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and renal function should be monitored.</paragraph>
                     </text>
                     <effectiveTime value="20231231"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_3c6cb848-62fe-460f-be4a-44e94490ba7d">
                     <id root="11314cd7-5189-4699-e063-6394a90a93b8"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>8.6 Use in Patients with Renal Impairment</title>
                     <text>
                        <paragraph>Patients with baseline renal impairment may be more susceptible to nephrotoxicity
 
  <content styleCode="italics">[see Warnings and Precautions (
  
   <linkHtml href="#ID_6e9a0c3a-9285-4a5a-aafd-221f0167daf1">5.1</linkHtml>)]
 
  </content>. Ensure adequate hydration before, during, and after cisplatin injection administration
 
  <content styleCode="italics">[see Dosage and Administration (
  
   <linkHtml href="#ID_afab3d6b-af05-4f01-9f88-54cfeb30c56c">2.1</linkHtml>)].
 
  </content>Measure serum creatinine, blood urea nitrogen, creatinine clearance, and serum electrolytes prior to initiating therapy, and as clinically indicated. Consider alternative treatments or reduce the dose of cisplatin injection for patients with baseline renal impairment or who develop significant reductions in creatinine clearance during treatment with cisplatin injection according to clinical treatment guidelines
 
  <content styleCode="italics">[see Dosage and Administration (
  
   <linkHtml href="#ID_f54f361a-b76e-4f4d-9e0a-7d8077a9af08">2.5</linkHtml>)].
 
  </content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20231231"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_69c2ad18-83db-4d0e-9d54-28bc4e2fc2ca">
               <id root="11314cd7-518a-4699-e063-6394a90a93b8"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>10 OVERDOSAGE</title>
               <text>
                  <paragraph>Acute overdosage with cisplatin injection may result in renal failure, hepatic failure, hearing loss, ocular toxicity, myelosuppression, nausea and vomiting, and neuritis. In addition, death can occur following overdosage.</paragraph>
                  <paragraph>Management of overdosage should include general supportive measures to sustain the patient through any period of toxicity that may occur. Important measures include renal protection by intravenous hydration with or without the use of an osmotic diuretic. Hemodialysis is not effective because of the high degree of protein binding of cisplatin injection. Plasmapheresis has been used to treat cases of cisplatin injection overdosage, but the optimal treatment regimen has not been established.</paragraph>
                  <paragraph>For current information on the management of poisoning or overdosage, contact the National Poison Control Center at 1-800-222-1222 or
 
  <linkHtml href="http://www.poison.org">www.poison.org</linkHtml>.

 </paragraph>
               </text>
               <effectiveTime value="20231231"/>
            </section>
         </component>
         <component>
            <section ID="ID_19ab2c3c-5599-4d43-83ff-c82674c6a001">
               <id root="11314cd7-518b-4699-e063-6394a90a93b8"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION</title>
               <text>
                  <paragraph>Cisplatin injection USP, a platinum-based drug for intravenous use, is a clear, colorless to pale yellow, sterile aqueous solution. Each 50 mL or 100 mL amber vial of Cisplatin Injection, USP, contains: 1 mg/mL cisplatin USP, 9 mg/mL sodium chloride, hydrochloric acid and/or sodium hydroxide to adjust pH, and water for injection to a final volume of 50 mL or 100 mL, respectively. The pH range of Cisplatin Injection, USP, is 3.5 to 5.0.</paragraph>
                  <paragraph>Cisplatin USP, the active ingredient in Cisplatin injection, is a yellow to orange crystalline powder with the molecular formula Cl
 
  <sub>2</sub>H
 
  <sub>6</sub>N
 
  <sub>2</sub>Pt and a molecular weight of 300.05. Cisplatin USP is a heavy metal complex containing a central atom of platinum surrounded by two chloride atoms and two ammonia molecules in the cis position. It is soluble in water or saline at 1 mg/mL and in dimethylformamide at 24 mg/mL. It has a melting point of 207°C.

 </paragraph>
                  <paragraph>The structural formula is:</paragraph>
                  <renderMultiMedia ID="id1655027566" referencedObject="MM1"/>
               </text>
               <effectiveTime value="20231231"/>
               <component>
                  <observationMedia ID="MM1">
                     <text>structural formula</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="cisplatin-structure.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_b2802455-ca52-46b5-8d81-8ee0b9e3d791">
               <id root="11314cd7-518c-4699-e063-6394a90a93b8"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20231231"/>
               <component>
                  <section ID="ID_f6c8d3b6-a217-4359-a822-b03fd3a7c40d">
                     <id root="11314cd7-518d-4699-e063-6394a90a93b8"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action</title>
                     <text>
                        <paragraph>The main mechanism of the cytotoxic action involves the binding of cisplatin to genomic DNA in the cell nucleus to form interstrand and intrastrand cross-links. This interferes with normal transcription and/or DNA replication mechanisms and triggers cytotoxic processes that lead to cell death.</paragraph>
                     </text>
                     <effectiveTime value="20231231"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_3aa692ce-642f-45e5-8bc8-12d79bd1e277">
                     <id root="11314cd7-518e-4699-e063-6394a90a93b8"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Distribution</content>
                        </paragraph>
                        <paragraph>Cisplatin dose not undergo the instantaneously and reversible binding to plasma protein that is characteristic of normal drug-protein binding. Platinum from cisplatin, but not cisplatin itself, becomes bound to several plasma proteins, including albumin, transferrin, and gamma globulin. Three hours after a bolus injection and 2 hours after the end of a 3 hour infusion, 90% of the plasma platinum is protein bound. The complexes between albumin and the platinum from cisplatin do not dissociate to a significant extent and are slowly eliminated with a minimum half-life of 5 days or more.</paragraph>
                        <paragraph>Following cisplatin doses of 20 mg/m
 
  <sup>2</sup>to 120 mg/m
 
  <sup>2</sup>, platinum is present in tissues for as long as 180 days after the last administration. With the exception of intracerebral tumors, platinum concentrations in tumors are generally somewhat lower than the concentrations in the organ where the tumor is located. Hepatic metastases have the highest platinum concentrations, but these are similar to the platinum concentrations in normal liver. Maximum red blood cell concentrations of platinum are reached within 90 to 150 minutes after a 100 mg/m
 
  <sup>2</sup>dose of cisplatin and decline in a biphasic manner with a terminal half-life of 36 to 47 days.

 </paragraph>
                        <paragraph>
                           <content styleCode="underline">Metabolism</content>
                        </paragraph>
                        <paragraph>The chlorine atoms of cisplatin are more subject to chemical displacement reactions by nucleophiles, such as water or sulfhydryl groups, than to enzyme-catalyzed metabolism. At physiological pH, the predominant molecular species are cisplatin and monohydroxymonochloro
 
  <content styleCode="italics">cis</content>-diamine platinum (II) in nearly equal concentrations. The latter, combined with the possible direct displacement of the chlorine atoms by sulfhydryl groups of amino acids or proteins, accounts for the instability of cisplatin in biological matrices. The ratios of cisplatin to total free (ultrafilterable) platinum in the plasma vary considerably between patients and range from 0.5 to 1.1 after a dose of 100 mg/m
 
  <sup>2</sup>.

 </paragraph>
                        <paragraph>
                           <content styleCode="underline">Elimination</content>
                        </paragraph>
                        <paragraph>Over a dose range of 40 mg to 140 mg cisplatin per m
 
  <sup>2</sup>given as a bolus injection or as infusions varying in length from 1 hour to 24 hours, from 10% to about 40% of the administered platinum is excreted in the urine in 24 hours. Over 5 days following administration of 40 mg/m
 
  <sup>2</sup>to 100 mg/m
 
  <sup>2</sup>doses given as rapid, 2 to 3 hour or 6 to 8 hour infusions, a mean of 35% to 51% of the dosed platinum is excreted in the urine. Similar mean urinary recoveries of platinum of about 14% to 30% of the dose are found following 5 daily administrations of 20 mg/m
 
  <sup>2</sup>per day, 30 mg/m
 
  <sup>2</sup>per day, or 40 mg/m
 
  <sup>2</sup>per day. Only a small percentage of the administered platinum is excreted beyond 24 hours post-infusion and most of the platinum excreted in the urine in 24 hours is excreted within the first few hours.

 </paragraph>
                        <paragraph>The parent compound, cisplatin, is excreted in the urine and accounts for 13% to 17% of the dose excreted within 1 hour after administration of 50 mg/m
 
  <sup>2</sup>. The mean renal clearance of cisplatin exceeds creatinine clearance and was 62 mL/min per m
 
  <sup>2</sup>and 50 mL/min per m
 
  <sup>2</sup>following administration of 100 mg/m
 
  <sup>2</sup>as 2 hour or 6 to 7 hour infusions, respectively.

 </paragraph>
                        <paragraph>Plasma concentrations of the parent compound, cisplatin, decrease monoexponentially with a half-life of about 20 to 30 minutes following bolus administrations of 50 mg/m
 
  <sup>2</sup>or 100 mg/m
 
  <sup>2</sup>doses. Monoexponential decreases and plasma half-lives of about 0.5 hour are also seen following 2 hour or 7 hour infusions of 100 mg/m
 
  <sup>2</sup>. After the latter, the total body clearances and volumes of distribution at steady-state for cisplatin are about 15 Liters per hour per m
 
  <sup>2</sup>to 16 Liters per hour per m
 
  <sup>2</sup>and 11 Liters per m
 
  <sup>2</sup>to 12 Liters per m
 
  <sup>2</sup>.

 </paragraph>
                        <paragraph>The renal clearance of free (ultrafilterable) platinum also exceeds the glomerular filtration rate, indicating that cisplatin or other platinum-containing molecules are actively secreted by the kidneys. The renal clearance of free platinum is nonlinear and variable and is dependent on dose, urine flow rate, and individual variability in the extent of active secretion and possible tubular reabsorption.</paragraph>
                        <paragraph>No significant relationships exist between the renal clearance of either free platinum or cisplatin and creatinine clearance.</paragraph>
                     </text>
                     <effectiveTime value="20231231"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_d18920c8-fdee-48d4-a5ac-280dc99dbb85">
               <id root="11314cd7-518f-4699-e063-6394a90a93b8"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY</title>
               <effectiveTime value="20231231"/>
               <component>
                  <section ID="ID_4788b4a3-3164-4dcd-8965-0bfb4655f979">
                     <id root="11314cd7-5190-4699-e063-6394a90a93b8"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <text>
                        <paragraph>The carcinogenic effect of cisplatin injection was studied in BDIX rats. Cisplatin injection was administered three times a week at 1 mg/kg body weight intraperitoneally to 50 BDIX rats for 3 weeks. Four hundred fifty-five days after the first application, 33 animals died, 13 of them related to malignancies (12 leukemias and 1 renal fibrosarcoma)
 
  <content styleCode="italics">[see Warnings and Precautions (
  
   <linkHtml href="#ID_10398218-037c-49d7-a8f9-ad7941942423">5.8</linkHtml>)].
 
  </content>
                        </paragraph>
                        <paragraph>Cisplatin is mutagenic in the bacteria reverse mutation (Ames) test and produces chromosome aberrations in mammalian cells.</paragraph>
                     </text>
                     <effectiveTime value="20231231"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_39a71328-d424-4918-b5ae-07e2d5594289">
               <id root="11314cd7-5191-4699-e063-6394a90a93b8"/>
               <code code="34093-5" codeSystem="2.16.840.1.113883.6.1" displayName="REFERENCES SECTION"/>
               <title>15 REFERENCES</title>
               <text>
                  <list listType="ordered">
                     <item>OSHA Hazardous Drugs. OSHA. http://www.osha.gov/SLTC/hazardousdrugs/index.html</item>
                  </list>
               </text>
               <effectiveTime value="20231231"/>
            </section>
         </component>
         <component>
            <section ID="ID_7c3db915-c6be-491c-ae2a-0d9b3899556e">
               <id root="11314cd7-5192-4699-e063-6394a90a93b8"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING</title>
               <text>
                  <paragraph>
                     <content styleCode="underline">How Supplied</content>
                  </paragraph>
                  <paragraph>Cisplatin injection, USP</paragraph>
                  <paragraph>
                     <content styleCode="bold">NDC</content>68001-283-24—Each multiple-dose amber vial contains 50 mg/50 mL (1 mg/mL) of cisplatin USP as a clear, colorless to pale yellow, sterile aqueous solution. 
  <br/>
                     <content styleCode="bold">NDC</content>68001-283-33—Each multiple-dose amber vial contains 100 mg/100 mL (1 mg/mL) of cisplatin USP as a clear, colorless to pale yellow, sterile aqueous solution.

 </paragraph>
                  <paragraph>
                     <content styleCode="bold">The above products are multiple dose vials packaged individually per shelf pack with NDC 68001-283-27 for 50mL and NDC 68001-283-32 for 100mL.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="underline">Storage</content>
                  </paragraph>
                  <paragraph>Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature]. Do not refrigerate or freeze cisplatin solution since a precipitate or crystal will form.</paragraph>
                  <paragraph>If precipitate or crystal observed inside the vial, keep it at recommended storage condition till clear solution obtained. Protect unopened container from light.</paragraph>
                  <paragraph>The cisplatin remaining in the amber vial following initial entry is stable for 28 days protected from light or for 7 days under fluorescent room light.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Handling and Disposal</content>
                  </paragraph>
                  <paragraph>Cisplatin injection, USP, is a cytotoxic drug. Follow applicable special handling and disposal procedures.
 
  <sup>1</sup>
                  </paragraph>
               </text>
               <effectiveTime value="20231231"/>
            </section>
         </component>
         <component>
            <section ID="ID_6cefe94a-b731-4932-bf8b-4cea2e50fe66">
               <id root="11314cd7-5193-4699-e063-6394a90a93b8"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION</title>
               <text>
                  <paragraph>
                     <content styleCode="underline">Nephrotoxicity</content>
                  </paragraph>
                  <paragraph>Inform patients that cisplatin injection can cause nephrotoxicity and that renal function and electrolyte monitoring during treatment is necessary. If indicated, inform patients about the use of electrolyte supplements
 
  <content styleCode="italics">[see Warnings and Precautions (
  
   <linkHtml href="#ID_6e9a0c3a-9285-4a5a-aafd-221f0167daf1">5.1</linkHtml>)].
 
  </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="underline">Peripheral Neuropathy</content>
                  </paragraph>
                  <paragraph>Advise patients to report any new paresthesias to their healthcare provider
 
  <content styleCode="italics">[see Warnings and Precautions (
  
   <linkHtml href="#ID_b32f4645-dc34-4112-b218-9428a497669a">5.2</linkHtml>)].
 
  </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="underline">Nausea and Vomiting</content>
                  </paragraph>
                  <paragraph>Advise patients concerning the use of antiemetics to prevent nausea and vomiting and to report persistent or severe symptoms to their healthcare provider
 
  <content styleCode="italics">[see Warnings and Precautions (
  
   <linkHtml href="#ID_ca1e8924-81c5-4f06-a8bb-e33df41b5533">5.3</linkHtml>)].
 
  </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="underline">Myelosuppression</content>
                  </paragraph>
                  <paragraph>Advise patients that cisplatin injection can reduce the absolute neutrophil count and the platelet count resulting in an increased risk of infection and bleeding and to contact their healthcare provider for new onset fever, symptoms of infection, or bleeding
 
  <content styleCode="italics">[see Warnings and Precautions (
  
   <linkHtml href="#ID_c34fe9ce-c1e5-4910-8758-5dd85942e97e">5.4</linkHtml>)].
 
  </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="underline">Ototoxicity</content>
                  </paragraph>
                  <paragraph>Advise patients to report any symptoms of hearing loss or vestibular dysfunction to their healthcare provider and that periodic monitoring of hearing may be performed
 
  <content styleCode="italics">[see Warnings and Precautions (
  
   <linkHtml href="#ID_e9fa4e2b-c9f5-45e8-9322-baf1fa26c5e7">5.6</linkHtml>)].
 
  </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="underline">Embryo-Fetal Toxicity</content>
                  </paragraph>
                  <list listType="unordered">
                     <item>Advise females of reproductive potential of the potential risk to a fetus and to inform their healthcare provider if they are pregnant or become pregnant
  
   <content styleCode="italics">[see Warnings and Precautions
   
    <linkHtml href="#ID_99ae58c0-ddba-40b6-a23a-2368409dc02b">5.9</linkHtml>and Use in Specific Populations
   
    <linkHtml href="#ID_0cdb87bd-bbc7-45a2-af4c-d769680df6de">8.1</linkHtml>)].
  
   </content>
                     </item>
                     <item>Advise females of reproductive potential to use effective contraception during treatment and for 14 months following the last dose of cisplatin injection
  
   <content styleCode="italics">[see Use in Specific Populations (
   
    <linkHtml href="#ID_00712a6a-6a34-4f21-9f37-f7bec57bf4f6">8.3</linkHtml>)].
  
   </content>
                     </item>
                     <item>Advise male patients with female partners of reproductive potential to use effective contraception during treatment and for 11 months following the last dose of cisplatin injection
  
   <content styleCode="italics">[see Use in Specific Populations (
   
    <linkHtml href="#ID_00712a6a-6a34-4f21-9f37-f7bec57bf4f6">8.3</linkHtml>)].
  
   </content>
                     </item>
                  </list>
                  <paragraph>
                     <content styleCode="underline">Lactation</content>
                  </paragraph>
                  <paragraph>Advise females not to breastfeed during treatment with cisplatin injection
 
  <content styleCode="italics">[</content>see
 
  <content styleCode="italics">Use in Specific Populations (
  
   <linkHtml href="#ID_2ba9d705-6681-4a33-bc2a-cd085d18d5ed">8.2</linkHtml>)].
 
  </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="underline">Infertility</content>
                  </paragraph>
                  <paragraph>Inform patients that treatment with cisplatin injection may lead to permanent impairment of spermatogenesis, ovarian failure or premature menopause, and reduced fertility in both genders
 
  <content styleCode="italics">[see Use in Specific Populations (
  
   <linkHtml href="#ID_00712a6a-6a34-4f21-9f37-f7bec57bf4f6">8.3</linkHtml>)]
 
  </content>.

 </paragraph>
                  <paragraph>
                     <content styleCode="underline">Alopecia</content>
                  </paragraph>
                  <paragraph>Inform patients that cisplatin injection can cause alopecia.</paragraph>
                  <list listType="ordered">
                     <item>
                        <content styleCode="bold">Manufactured By:</content>
                        <br/>  Intas Pharmaceuticals Limited, 
   <br/>  Plot No. 5 to 14 Pharmez, 
   <br/>  Nr. Village Matoda, 
   <br/>  Bavla Road, Ta.- Sanand, 
   <br/>  Dist. Ahmedabad - 382213, 
   <br/>  India
 
  </item>
                  </list>
                  <paragraph>For BluePoint Laboratories</paragraph>
                  <paragraph>51 0369 2 734143</paragraph>
                  <paragraph>Issued: December 2023</paragraph>
               </text>
               <effectiveTime value="20231231"/>
            </section>
         </component>
         <component>
            <section ID="ID_ff636222-e104-4a38-a7c6-c6f5ecd75534">
               <id root="11314cd7-5194-4699-e063-6394a90a93b8"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PACKAGE/LABEL PRINCIPAL DISPLAY PANEL</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">Cisplatin Injection</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">50 mL Multiple Dose Vial (1 mg/mL)- Carton</content>
                  </paragraph>
                  <renderMultiMedia ID="id1052" referencedObject="MM2"/>
                  <paragraph>
                     <content styleCode="bold">50 mL Multiple Dose Vial (1 mg/mL)- Label</content>
                  </paragraph>
                  <renderMultiMedia ID="id1055" referencedObject="MM3"/>
                  <paragraph>
                     <content styleCode="bold">100 mL Multiple Dose Vial (1 mg/mL)- Carton</content>
                  </paragraph>
                  <renderMultiMedia ID="id1058" referencedObject="MM4"/>
                  <paragraph>
                     <content styleCode="bold">100 mL Multiple Dose Vial (1 mg/mL)- Label</content>
                  </paragraph>
                  <renderMultiMedia ID="id1061" referencedObject="MM5"/>
               </text>
               <effectiveTime value="20231231"/>
               <component>
                  <observationMedia ID="MM2">
                     <text>CISPLATIN INJECTION USP 50ML CARTONS Rev 12_23</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="cisplatin-inj-50mg-carton.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM3">
                     <text>CISPLATIN INJECTION USP 50ML Label Rev 12_23</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="cisplatin-inj-50mg-label.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM4">
                     <text>CISPLATIN INJECTION USP 100ML CARTONS Rev 12_23</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="cisplatin-inj-100mg-carton.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM5">
                     <text>CISPLATIN INJECTION USP 100ML Label Rev 12_23</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="cisplatin-inj-100mg-label.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>